Gland Pharma cash flow

Latest FY26

Cash from operations: ₹1,031cr+12.8% on FY25
Capital spending: ₹494cr+25.4% on FY25
Free cash flow: ₹537cr+3.1% on FY25
Cash from financing: −₹417cr−₹433 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	424	378	345	147
	—	33.3	42.0	19.7	6.2
	—	−206	0.0	0.0	−179
	—	45.5	0.0	0.0	0.0
	—	−41.8	0.0	−13.0	1.5
	—	24.7	6.4	21.4	65.8
	—	−2.9	−214	−149	−2.7
	—	18.7	−19.9	666	−760
	—	−279	42.3	−325	144
	—	0.0	−164	−5.1	36.0
	—	83.6	0.0	0.0	0.0
	—	−54.9	26.9	−379	121
	—	−23.3	0.0	0.0	0.0
	—	0.0	109	−10.4	40.7
Cash from operating activities
	1,587	1,465	1,063	1,133	1,055
	—	22.3	206	170	−380
	—	1,487	1,269	1,303	675
	—	455	354	306	311
	—	1,031	915	997	364
Cash from investing activities
	—	491	385	390	221
	—	3.7	9.6	8.3	2.2
	—	0.0	0.3	0.8	0.1
	—	0.6	0.0	0.0	0.0
	—	0.0	0.0	1,022	0.0
	—	232	156	137	161
	—	399	1,942	−475	1,271
	—	138	1,705	−1,757	1,208
Cash from financing activities
	—	0.0	2.5	0.5	21.5
	—	22.5	5.3	21.0	0.0
	—	93.8	62.8	777	0.1
	—	16.8	18.3	18.1	0.2
	—	—	—	2.1	0.0
	—	32.4	30.6	23.5	6.2
	—	297	329	0.0	0.0
	—	−417	−433	−799	14.9
	—	752	2,186	−1,560	1,587
	—	50.8	13.1	7.7	3.0
	—	803	2,199	−1,552	1,590
	—	—	2,556	357	1,909
Reference items
	1,751	1,630	1,269	1,333	1,025
	26.0%	25.3%	22.6%	23.5%	28.3%
	537	537	521	599	141
	—	479	439	891	—
	₹32.59	₹32.59	₹31.60	₹36.33	₹8.55
	86.38×	—	—	—	—
	—	1.00×	1.31×	1.29×	0.47×
	—	455	354	306	311
	—	32.4	30.6	23.5	6.2

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAND₹2,815.00

Gland Pharma Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB AUROPHARMA PPLPHARMA SYNGENE WOCKPHARMA ASTERDM COHANCE LALPATHLABMcap ₹46,380 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	146.7	344.6	377.9	423.7	—
+ Finance Costs	6.2	19.7	42.0	33.3	—
+ Interest Income	-179.4	0.0	0.0	-205.5	—
+ Share-based Payments	0.0	0.0	0.0	45.5	—
+ Unrealised FX (Gain) / Loss	1.5	-13.0	0.0	-41.8	—
+ Other Non-cash Items	65.8	21.4	6.4	24.7	—
+ Other — Cash Effects are Investing / Financing	-2.7	-149.1	-214.4	-2.9	—
Changes in Working Capital
+ Inventories	-759.6	666.1	-19.9	18.7	—
+ Trade Receivables — Current	144.0	-325.0	42.3	-278.6	—
+ Other Current Assets	36.0	-5.1	-164.3	0.0	—
+ Other Non-current Assets	0.0	0.0	0.0	83.6	—
+ Trade Payables — Current	121.0	-378.9	26.9	-54.9	—
+ Other Financial Liabilities — Non-current	0.0	0.0	0.0	-23.3	—
+ Other Current Liabilities	40.7	-10.4	109.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	1,054.6	1,132.5	1,062.7	1,464.6	1,586.8
+ Total Adjustments (incl. Working Capital)	-379.7	170.4	205.9	22.3	—
Cash from Operations (pre-tax)	674.8	1,302.9	1,268.5	1,486.8	—
+ Income Taxes Paid	310.9	306.1	353.8	455.5	—
Cash from Operating Activities	364.0	996.8	914.7	1,031.4	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	220.9	389.9	384.5	490.8	—
+ Acq of Intangible Assets	2.2	8.3	9.6	3.7	—
+ Disp of Fixed Assets	0.1	0.8	0.3	0.0	—
+ Disp of Investment Property	0.0	0.0	0.0	0.6	—
+ Acq of Subsidiaries / Businesses (net)	0.0	1,021.8	0.0	0.0	—
+ Interest Received — Investing	160.6	137.1	156.5	232.3	—
+ Other Inflows / (Outflows) — Investing	1,270.6	-474.7	1,942.1	399.3	—
Cash from Investing Activities	1,208.2	-1,756.9	1,704.7	137.7	—
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options	21.5	0.5	2.5	0.0	—
+ Proceeds from Borrowings	0.0	21.0	5.3	22.5	—
+ Repayment of Borrowings	0.1	777.3	62.8	93.8	—
+ Payment of Lease Liabilities	0.2	18.1	18.3	16.8	—
+ Payment of Finance Lease Liabilities	0.0	2.1	—	—	—
+ Interest Paid	6.2	23.5	30.6	32.4	—
+ Dividends Paid	0.0	0.0	329.5	296.6	—
Cash from Financing Activities	14.9	-799.4	-433.5	-417.0	—
Net Changes in Cash (pre-FX)	1,587.1	-1,559.5	2,186.0	752.1	—
+ Effect of FX Rate Changes on Cash	3.0	7.7	13.1	50.8	—
Net Changes in Cash	1,590.1	-1,551.8	2,199.1	802.9	—
Closing Cash	1,908.9	357.1	2,556.2	—	—
Reference Items
EBITDA	1,024.8	1,333.1	1,268.9	1,629.5	1,751.1
EBITDA Margin %	28.27	23.53	22.59	25.34	26.04
Free Cash Flow (CFO − Capex)	140.8	598.5	520.6	537.0	537.0
Free Cash Flow to Equity	—	891.0	439.4	478.7	—
Free Cash Flow per Basic Share	8.55	36.33	31.60	32.59	32.59
Price to Free Cash Flow	—	—	—	—	86.38
Cash Flow to Net Income	0.47	1.29	1.31	1.00	—
Cash Paid for Taxes	310.9	306.1	353.8	455.5	—
Cash Paid for Interest	6.2	23.5	30.6	32.4	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.